

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/003,674

10/23/2001

M. Michael Wolfe

50128/002003

21559 CLARK & ELBING LLP 176 FEDERAL STREET BOSTON, MA 02110-2214



CONFIRMATION NO. 8781
FORMALITIES LETTER
OC000000007395758

Date Mailed: 01/31/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
 the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
 indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
 substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
 of the sequence listing information recorded in computer readable form is identical to the written (on paper
 or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center





Initial Patent Examination Division (703) 308-1202 PART 2 - COPY TO BE RETURNED WITH RESPONSE



N 03CO Box Seg

PATENT ATTORNEY DOCKET NO. 50128/002003

Certificate of Mailing: Date of Deposit: 16. 12, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(Wie H Bowen

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Michael Wolfe et al.

Art Unit:

Unassigned

Serial No.:

10/003,674

Examiner:

Unassigned

Filed:

October 23, 2001

Customer No.:

21559

Title:

SPECIFIC ANTAGONISTS FOR GLUCOSE-DEPENDENT

INSULINOTROPIC POLYPEPTIDE (GIP)

Assistant Commissioner for Patents Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In reply to the Notice To Comply mailed January 31, 2002, Applicant submits the following:

- A substitute paper copy of the sequence listing and an amendment directing its entry into the specification.
- A substitute copy of the sequence listing in computer readable form.
- A statement that the contents of the paper and computer readable copies are the same and contain no new matter.
- A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

If there are any charges, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: February 22,2002

Paul T. Clark

M. Michaud Susan M. Michaud

Reg. No. 30,162

Reg. No. 42,885

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

21550

A TOUT DATENT TRADEMARK OFFICE

F:\50128\50128.002003 Reply to Notice to Comply with Seq. Requirements.wpd